Twist Bioscience Corporation (NASDAQ:TWST) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $115.27.

A number of brokerages have recently weighed in on TWST. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. BWS Financial restated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. UBS Group began coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. Finally, Piper Sandler raised their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily Leproust sold 5,203 shares of Twist Bioscience stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $177.38, for a total transaction of $922,908.14. Following the completion of the transaction, the chief executive officer owned 613,699 shares in the company, valued at approximately $108,857,928.62. The trade was a 0.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 294 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $165.49, for a total value of $48,654.06. Following the sale, the senior vice president directly owned 116,720 shares of the company’s stock, valued at $19,315,992.80. This represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 521,777 shares of company stock worth $78,416,543. 3.08% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new stake in Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio purchased a new position in Twist Bioscience during the 1st quarter worth $33,000. Strategic Advocates LLC grew its stake in shares of Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after acquiring an additional 453 shares in the last quarter. Finally, Leonteq Securities AG purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at about $48,000.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $188.05 on Friday. Twist Bioscience has a one year low of $23.30 and a one year high of $200.31. The firm has a market capitalization of $11.79 billion, a price-to-earnings ratio of -84.71 and a beta of 2.19. The business has a 50-day simple moving average of $134.43 and a 200 day simple moving average of $91.41. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the company posted $0.33 earnings per share. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, research analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.